Navigation Links
Controversial Cholesterol Drug Might Lower Blood Sugar Levels in Diabetics
Date:7/19/2011

By Serena Gordon
HealthDay Reporter

MONDAY, July 18 (HealthDay News) -- Australian researchers have discovered that a drug initially designed to raise levels of "good" HDL cholesterol has an unexpected benefit in people with type 2 diabetes: it lowered their blood sugar.

That's the good news.

The bad news is that this particular medication, torcetrapib, also has a significantly increased risk of cardiovascular problems and mortality. In fact, the problems were so significant with torcetrapib that the initial trial, known as ILLUMINATE, was halted early. However, there are two other medications -- dalcetrapib and anacetrapib -- in the same drug class as torcetrapib that don't appear to have the same heart risks, according to the study authors.

What remains to be seen is if these other drugs have the same benefits that torcetrapib did.

"Diabetic patients in the ILLUMINATE trial who received the combination of atorvastatin plus torcetrapib had lower levels of [short-term and long-term blood sugar] than those receiving atorvastatin alone, indicating that treatment with torcetrapib, compared with placebo, resulted in improvement in diabetic control," wrote the Australian researchers.

Atorvastatin, better known by its brand name, Lipitor, is a statin that's commonly prescribed to reduce levels of LDL, or "bad," cholesterol.

Results of the Australian study are published in the Aug. 2 issue of Circulation.

Type 2 diabetes is a major risk factor for the development of cardiovascular disease, and significantly increases the likelihood of having a heart attack, according to background information in the study. Dyslipidemia (which means high LDL levels and low HDL levels) is common for people with type 2 diabetes.

The drug torcetrapib is from a class of medications called CETP inhibitors. These drugs help raise levels of HDL cholesterol.

The ILLUMINATE trial included 6,661 people with type 2 diabetes between the ages of 45 and 75. Almost 4,000 of the people with type 2 diabetes had a history of cardiovascular disease at the start of the study.

All of the study participants were given lifestyle education and the LDL-lowering drug, atorvastatin. They were then randomly placed into one of two groups: one group received 60 milligrams of torcetrapib daily, while the other group received placebo pills.

The trial was stopped in 2006 when it was determined that people in the torcetrapib group had significantly more cardiovascular problems and deaths than those in the placebo group. According to the Australian researchers, the increased risk of cardiovascular problems probably wasn't due to the CETP inhibition, but to other actions of the drug. They suspect that the other medications in this class of medicines won't have the same detrimental effects.

For the current study, the researchers went back through the data to examine the drug's effect on blood sugar. They found fasting blood sugar levels were lower for the torcetrapib group, and hemoglobin A1C levels (a test that provides a two- to three-month average of blood sugar levels) were also lower -- 7.29 percent in the placebo group and 7.06 percent in the torcetrapib group, according to the study.

"This is a mild drop in blood sugar. For someone who averages 150 milligrams per deciliter (mg/dL) each day, this would bring them down to around 140 mg/dL," explained Dr. Spyros Mezitis, an attending endocrinologist at Lenox Hill Hospital in New York City.

"I don't think these are powerful anti-diabetic agents, but it's an added effect, and it makes sense if we can treat several risk factors with one drug," said Dr. Joel Zonszein, director of the Clinical Diabetes Center at Montefiore Medical Center in New York City.

Zonszein said there's no clear explanation for how this medication might be lowering blood sugar levels, but notes that type 2 diabetes and cholesterol problems are very closely related.

Both Zonszein and Mezitis said it remains to be seen whether or not the other drugs in this class of medications will be safer than torcetrapib, and whether they also have the same effects on blood sugar levels.

Mezitis added, "This won't change practice for now. We need more studies to understand the pathophysiology, and we need solid cardiovascular evidence for the other agents in this class."

More information

To learn more about the connection between type 2 diabetes and cholesterol, visit the American Diabetes Association.

SOURCES: Spyros Mezitis, M.D., attending endocrinologist and clinical investigator, Lenox Hill Hospital, New York City; Joel Zonszein, M.D., director, Clinical Diabetes Center, Montefiore Medical Center, New York City; Aug. 2, 2011, Circulation


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Controversial TOFT theory of cancer versus SMT model: Authors do battle in BioEssays
2. Recommendations issued on controversial Ashley procedure for disabled children
3. K-State receives patent for noncontroversial source of stem cells
4. Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged
5. Controversial urological issues top EAUs Anniversary Congress in Barcelona
6. Project Prevention Brings Controversial Sterilization Program to Honolulu
7. Scientists Discover Ultra-Bad Cholesterol
8. Experts Say Cholesterol Screenings Should Start in Childhood
9. Selenium Supplements Might Give Modest Benefit Against Cholesterol
10. Bad cholesterol not as bad as people think, shows Texas A&M study
11. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Controversial Cholesterol Drug Might Lower Blood Sugar Levels in Diabetics
(Date:2/12/2016)... ... ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. ... “Those who don’t learn from history are doomed to repeat it.” , An analysis of ... year. But that takes time. , Take a close look at the warning letters ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO ... Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern ... Nevada Healthcare System. This will be the first Fisher House in Nevada, and ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , February 12, 2016 /PRNewswire/ ... nicht anders vermerkt)   http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... des Unternehmens http://www.telestatherapeutics.com abrufbar.    ... (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des ...
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
Breaking Medicine Technology: